Enduring the Downturn

This was intended to be a "good news/bad news" report on the current state of biotechnology hiring. As it turns out, the bad news is that I can't find anything for the "good" piece of that equation. With the war adding to the general insecurity that many feel, the job market isn't a real pleasure to be a part of right now. As a biotechnology headhunter, I've staffed young companies and helped them manage the development of new medicines. Now these same firms are in need of a fix themselves, a

Written byDavid Jensen
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

This was intended to be a "good news/bad news" report on the current state of biotechnology hiring. As it turns out, the bad news is that I can't find anything for the "good" piece of that equation. With the war adding to the general insecurity that many feel, the job market isn't a real pleasure to be a part of right now.

As a biotechnology headhunter, I've staffed young companies and helped them manage the development of new medicines. Now these same firms are in need of a fix themselves, as they face the single worst crunch of their existence: a one-two punch from the economy and turned-off investors. Every day I hear reports of companies cutting back, laying off, or just going out of business. Industry insiders are split regarding how long this retrenching period will last but they are unanimous as to what will result: closures and consolidations ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies